Latest News for: ckap2

Edit

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, ...

Business Wire 18 Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #AACR26--Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026 ... .
Edit

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

Pharmiweb 17 Apr 2026
Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a novel therapeutic approach in cancer ... protein 2 (CKAP2) pathway.
Edit

Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at ...

Business Wire 18 Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #AACR26--Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026 ... .
Edit

Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026

Pharmiweb 18 Mar 2026
The AACR presentation will describe the discovery and preclinical characterization of STX-6398, an oral small molecule that modulates CKAP2 and its downstream signaling pathways ... “CKAP2 sits at the ...
  • 1

Article Search

tools
×
×
×
×